

# Accepted Manuscript

Discovery and Characterization of Aryl Isonitriles as A New Class of Compounds versus Methicillin- and Vancomycin-resistant *Staphylococcus aureus*

Dexter C. Davis, Haroon Mohammad, Kwaku Kyei-Baffour, Waleed Younis, Cassidy Noel Creemer, Mohamed N. Seleem, Mingji Dai



PII: S0223-5234(15)30107-0

DOI: [10.1016/j.ejmech.2015.06.031](https://doi.org/10.1016/j.ejmech.2015.06.031)

Reference: EJMECH 7958

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 27 March 2015


Revised Date: 9 June 2015

Accepted Date: 13 June 2015

Please cite this article as: D.C. Davis, H. Mohammad, K. Kyei-Baffour, W. Younis, C.N. Creemer, M.N. Seleem, M. Dai, Discovery and Characterization of Aryl Isonitriles as A New Class of Compounds versus Methicillin- and Vancomycin-resistant *Staphylococcus aureus*, *European Journal of Medicinal Chemistry* (2015), doi: 10.1016/j.ejmech.2015.06.031.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


Insert Table of Contents Graphic and Synopsis Here.



**13**

MIC as low as **2 μM** against MRSA and VRSA  
No toxicity at **64 μM** against mammalian cells

versus



**43** (MIC > 128 μM)

A novel class of aryl isonitrile compounds has been discovered as potent antimicrobial compounds against several clinically relevant MRSA and VRSA isolates without any toxicity against mammalian cells up to a concentration of 64 μM.

Download English Version:

<https://daneshyari.com/en/article/7799416>

Download Persian Version:

<https://daneshyari.com/article/7799416>

[Daneshyari.com](https://daneshyari.com)